Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms.
Ontology highlight
ABSTRACT: In the U.S., the prevalence of small cell lung cancer (SCLC) is declining, probably reflecting the decreasing prevalence of tobacco use. However, a significant number of patients will receive a diagnosis of SCLC, and approximately 40% of patients with SCLC will have limited-stage (LS) disease, which is potentially curable with the combination of chemotherapy and radiation therapy. The standard therapy for LS-SCLC is concurrent chemoradiotherapy, and the 5-year survival rate observed in clinical trials is approximately 25%. The standard chemotherapy remains cisplatin and etoposide, but carboplatin is frequently used in patients who cannot tolerate or have a contraindication to cisplatin. Substantial improvements in survival have been made through improvements in radiation therapy. Concurren
SUBMITTER: Stinchcombe TE
PROVIDER: S-EPMC3227940 | biostudies-literature | 2010
REPOSITORIES: biostudies-literature
ACCESS DATA